24 This opens the door to exploring these novel compounds as potential therapeutic agents in a broader range of conditions
Obesity research consistently shows that the biological changes driving weight regain persist long after weight is lost
If GLP-1 agonists pose a similar risk, thats important to knowand if they dont, it could further accelerate the sea change occurring in our approach to treating obesity. The studys results, published in JAMA Psychiatry , suggest that the similarities in outcome between the two approaches do not include that potential downside
Talking with a clinician who knows your full medical history is the best way to learn whether a GLP-1 might benefit you
Weight loss in particular, but also cardiorenal benefits and other potential advantages, have encouraged wider use, and several further GLP-1RAs with ever longer circulating half-lives are advancing in development, aiming to leverage the convenience of administration with minimal gastrointestinal side effects (Table 2) [37]
The TRIUMPH-3 cardiovascular outcomes trial is underway, with results expected in 2027 and that data will be central to full FDA review
